NasdaqCM - Nasdaq Real Time Price USD

Bio-Path Holdings, Inc. (BPTH)

0.1850

+0.0050

+(2.78%)

At close: May 16 at 3:19:47 PM EDT

Bio-Path: Q1 Earnings Snapshot

BELLAIRE, Texas (AP) — Bio-Path Holdings Inc. BPTH) on Thursday reported a loss of $2.9 million in its first quarter. The Bellaire, Texas-based company said it had a loss of 40 cents per share.

Associated Press Finance 3 days ago

BPTH
+2.78%
Bio-Path Holdings Achieves Third Pre-Clinical Milestone Confirming Potential of BP1001-A as Treatment for Obesity in Type 2 Diabetes Patients

Data suggest BP1001-A prevents fatty acid-induced insulin resistance in cellsHOUSTON, May 01, 2025 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (OTCQB:BPTH), a biotechnology company leveraging its proprietary DNAbilize® liposomal delivery and antisense technology to develop a portfolio of targeted nucleic acid cancer and obesity drugs, today reported the achievement of a third milestone from recent preclinical studies of BP1001-A that provide additional support for its potential as a treatment f

GlobeNewswire 17 days ago

BPTH
+2.78%
Bio-Path Holdings Reports Full Year 2024 Financial Results

Reports Continued Progress Across Both Obesity and Oncology FranchisesHOUSTON, March 28, 2025 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (OTCQB:BPTH), a biotechnology company leveraging its proprietary DNAbilize® antisense RNAi nanoparticle technology to develop a portfolio of targeted nucleic acid cancer and obesity drugs, today announced its financial results for the year ended December 31, 2024 and provided an update on recent corporate developments. “We are merely touching the tip of the i

GlobeNewswire last month

BPTH
+2.78%
Bio-Path Holdings Announces Pre-Clinical Results Signaling Increased Potential for BP1001-A as Treatment for Obesity in Type 2 Diabetes Patients

Recent Pre-Clinical Studies Showed BP1001-A Attenuated Fatty Acid-Induced Insulin Resistance and Restored Insulin Sensitivity in Muscle Progenitor and Skeletal Muscle Fiber Cell ModelsHOUSTON, March 18, 2025 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (OTCQB:BPTH), a biotechnology company leveraging its proprietary DNAbilize® liposomal delivery and antisense technology to develop a portfolio of targeted nucleic acid cancer and obesity drugs, today reported results from recent preclinical studie

GlobeNewswire last month

BPTH
+2.78%
Bio-Path Holdings Expands Global Patent Portfolio

Builds on Global Intellectual Property Portfolio to Protect DNAbilize® PlatformHOUSTON, Feb. 13, 2025 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnology company leveraging its proprietary DNAbilize® liposomal delivery and antisense technology to develop a portfolio of targeted nucleic acid cancer and obesity drugs, today announced the receipt of newly issued patents in the United States and New Zealand, and updated investors on the extent of its global intellectual prope

GlobeNewswire 3 months ago

BPTH
+2.78%
Bio-Path Holdings Provides Key Clinical Updates

First Solid Tumor Patient Treated with Second, Higher Dose in Phase 1/1b BP1001-A Clinical Trial Experienced Tumor Reduction and Continued Stable Disease Reports Continued Patient Progress from Phase 2 Triple Combination Study of Prexigebersen in Acute Myeloid Leukemia (AML) HOUSTON, Feb. 13, 2025 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnology company leveraging its proprietary DNAbilize® liposomal delivery and antisense technology to develop a portfolio of targeted

GlobeNewswire 3 months ago

BPTH
+2.78%
$Bio-Path Holdings Provides Update from Phase 1/1b Clinical Trial of BP1002 for Treatment of Refractory/Relapsed Acute Myeloid Leukemia$

Bio-Path Holdings Provides Update from Phase 1/1b Clinical Trial of BP1002 for Treatment of Refractory/Relapsed Acute Myeloid Leukemia

Study Progresses to Fourth Higher 90 mg/m2 Dose Cohort Compelling Patient Response Highlighted by Stable Disease and Significant Reduction in Blast Count After One Treatment Cycle HOUSTON, Feb. 12, 2025 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnology company leveraging its proprietary DNAbilize® liposomal delivery and antisense technology to develop a portfolio of targeted nucleic acid cancer and obesity drugs, today provides an update from the Company’s ongoing Phase

GlobeNewswire 3 months ago

BPTH
+2.78%
Bio-Path Holdings Provides 2025 Clinical and Operational Update

Advancing Multiple Programs in Areas of Significant Unmet Medical Need Several Milestones Across Clinical Development Pipeline Expected in 2025 HOUSTON, Jan. 10, 2025 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnology company leveraging its proprietary DNAbilize® liposomal delivery and antisense technology to develop a portfolio of targeted nucleic acid cancer and obesity drugs, today provides a clinical development and operational update for 2025. “The important work we

GlobeNewswire 4 months ago

BPTH
+2.78%
Bio-Path Holdings Announces Preclinical Testing of BP1001-A as Potential Treatment for Obesity in Type 2 Diabetes Patients Enhances Insulin Sensitivity

Preclinical Studies Confirmed BP1001-A Mechanism of Action and Therapeutic Potential in Obesity and Type 2 DiabetesHOUSTON, Dec. 19, 2024 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnology company leveraging its proprietary DNAbilize® liposomal delivery and antisense technology to develop a portfolio of targeted nucleic acid cancer drugs, today reported that results from preclinical studies of BP1001-A for obesity demonstrated enhanced insulin sensitivity, confirming BP1

GlobeNewswire 4 months ago

BPTH
+2.78%
Stonegate Capital Partners Updates Coverage on Bio-Path Holdings, Inc. (BPTH) Q3 24

Dallas, Texas--(Newsfile Corp. - December 13, 2024) - Bio-Path Holdings, Inc. (NASDAQ: BPTH): Stonegate Capital Partners Updates Coverage on Bio-Path Holdings, Inc. (NASDAQ: BPTH) for Q3 2024. To view the full announcement, including downloadable images, bios, and more, click here. Click image ...

Newsfile 5 months ago

BPTH
+2.78%
Bio-Path Holdings Outlines Rationale for Development of BP1001-A as Potential Treatment for Obesity in Type 2 Diabetes Patients

Extensive Scientific Evidence Supporting Growth Factor Receptor Bound Protein-2 (Grb2) as Fundamental Link in Insulin Resistance Reallocates Resources to Metabolic Program and Discontinues Enrollment in Phase 1 Study of BP1002 to Treat Relapsed/Refractory Lymphoma and Relapsed/Refractory Chronic Lymphocytic Leukemia Due to Enrollment Challenges in Niche Patient Populations HOUSTON, Dec. 11, 2024 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnology company leveraging its pr

GlobeNewswire 5 months ago

BPTH
+2.78%
Bio-Path Holdings Inc (BPTH) Q3 2024 Earnings Call Highlights: Strategic Advances and Financial ...

Bio-Path Holdings Inc (BPTH) reports progress in clinical trials and improved financial performance despite cash reserve challenges.

GuruFocus.com 5 months ago

BPTH
+2.78%
Bio-Path: Q3 Earnings Snapshot

BELLAIRE, Texas (AP) — Bio-Path Holdings Inc. BPTH) on Thursday reported a loss of $2.1 million in its third quarter. The Bellaire, Texas-based company said it had a loss of 70 cents per share.

Associated Press Finance 5 months ago

BPTH
+2.78%
Bio-Path Holdings Reports Third Quarter 2024 Financial Results

Expands DNAbilize® Technology Beyond Oncology into Obesity Conference Call to be Held Today at 8:30 A.M. ET HOUSTON, Nov. 15, 2024 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnology company leveraging its proprietary DNAbilize® antisense RNAi nanoparticle technology to develop a portfolio of targeted nucleic acid cancer drugs, today announced its financial results for the third quarter ended September 30, 2024 and provided an update on recent corporate developments. “The

GlobeNewswire 5 months ago

BPTH
+2.78%
Bio-Path Holdings to Announce Third Quarter 2024 Financial Results on November 15, 2024

HOUSTON, Nov. 08, 2024 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ: BPTH) a biotechnology company leveraging its proprietary DNAbilize® antisense RNAi nanoparticle technology to develop a portfolio of targeted nucleic acid cancer drugs, today announced that it will host a live conference call and audio webcast on Friday, November 15, 2024 at 8:30 a.m. ET to report financial results for the third quarter ended September 30, 2024 and to provide a business overview. To access the live conf

GlobeNewswire 6 months ago

BPTH
+2.78%
Bio-Path Holdings Announces Closing of $4.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules

HOUSTON, Oct. 10, 2024 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc. (NASDAQ:BPTH) (“Bio-Path” or the “Company”), a biotechnology company leveraging its proprietary DNAbilize® liposomal delivery and antisense technology to develop a portfolio of targeted nucleic acid cancer drugs, today announced that it has closed its previously announced private placement priced at-the-market under Nasdaq rules for the issuance and sale of an aggregate of 4,597,702 shares of its common stock (or common stock equ

GlobeNewswire 7 months ago

BPTH
+2.78%
Bio-Path Holdings Inc (BPTH) Q2 2024 Earnings Call Highlights: Financial Improvements and ...

Bio-Path Holdings Inc (BPTH) reports reduced net loss and advances in clinical trials, strengthening its position in the fight against AML.

GuruFocus.com 7 months ago

BPTH
+2.78%
ACHR, BPTH, PLUG, REGRF:

Leaders Report Latest Advances NEW YORK, NY / ACCESSWIRE / October 8, 2024 / Electric Aviation, Obesity Treatment, Clean Energy and Digital Transformation of $31 Billion Watch Market Wall Street Reporter, the trusted name in financial news since 1843, ...

ACCESS Newswire 7 months ago

REGRF

PLUG

BPTH
+2.78%
Nano-Cap Bio-Path Takes Plunge In Weight Loss Race, Initiates Obesity Program With Drug Candidate Under Development For Blood Cancer

Bio-Path Holdings, Inc., (NASDAQ:BPTH) stock is trading higher on Tuesday with a strong session volume of 25.89 million compared to an average of 328.97K as per data from Benzinga Pro. The company initiated a therapeutic program to develop BP1001-A for treating obesity and related metabolic diseases. This program marks the first application of DNAbilize technology to develop a non-cancer application. The company expects to begin preclinical studies to confirm these assumptions in the fourth quar

Benzinga 7 months ago

BPTH
+2.78%
Bio-Path Holdings Initiates Development of Therapeutic Program for Treatment of Obesity

HOUSTON, Oct. 08, 2024 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnology company leveraging its proprietary DNAbilize® liposomal delivery and antisense technology to develop a portfolio of targeted nucleic acid cancer drugs, today announced the initiation of a therapeutic program to develop BP1001-A for the treatment of obesity and related metabolic diseases. This program marks the first application of DNAbilize technology for development of a non-cancer application, wh

GlobeNewswire 7 months ago

BPTH
+2.78%

Performance Overview

Return	BPTH	S&P 500 (^GSPC)
YTD	-84.05%	+1.30%
1-Year	-92.09%	+12.48%
3-Year	-99.71%	+48.66%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Bio-Path Holdings, Inc. (BPTH)

Bio-Path: Q1 Earnings Snapshot

Bio-Path Holdings Achieves Third Pre-Clinical Milestone Confirming Potential of BP1001-A as Treatment for Obesity in Type 2 Diabetes Patients

Bio-Path Holdings Reports Full Year 2024 Financial Results

Bio-Path Holdings Announces Pre-Clinical Results Signaling Increased Potential for BP1001-A as Treatment for Obesity in Type 2 Diabetes Patients

Bio-Path Holdings Expands Global Patent Portfolio

Bio-Path Holdings Provides Key Clinical Updates

Bio-Path Holdings Provides Update from Phase 1/1b Clinical Trial of BP1002 for Treatment of Refractory/Relapsed Acute Myeloid Leukemia

Bio-Path Holdings Provides 2025 Clinical and Operational Update

Bio-Path Holdings Announces Preclinical Testing of BP1001-A as Potential Treatment for Obesity in Type 2 Diabetes Patients Enhances Insulin Sensitivity

Stonegate Capital Partners Updates Coverage on Bio-Path Holdings, Inc. (BPTH) Q3 24

Bio-Path Holdings Outlines Rationale for Development of BP1001-A as Potential Treatment for Obesity in Type 2 Diabetes Patients

Bio-Path Holdings Inc (BPTH) Q3 2024 Earnings Call Highlights: Strategic Advances and Financial ...

Bio-Path: Q3 Earnings Snapshot

Bio-Path Holdings Reports Third Quarter 2024 Financial Results

Bio-Path Holdings to Announce Third Quarter 2024 Financial Results on November 15, 2024

Bio-Path Holdings Announces Closing of $4.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules

Bio-Path Holdings Inc (BPTH) Q2 2024 Earnings Call Highlights: Financial Improvements and ...

ACHR, BPTH, PLUG, REGRF:

Nano-Cap Bio-Path Takes Plunge In Weight Loss Race, Initiates Obesity Program With Drug Candidate Under Development For Blood Cancer

Bio-Path Holdings Initiates Development of Therapeutic Program for Treatment of Obesity

Performance Overview